Skip to main content
SpringerLink
Log in

Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings

  • Conference paper
Local Therapies for Glioma Present Status and Future Developments

Part of the book series: Acta Neurochirurgica Supplements ((NEUROCHIRURGICA,volume 88))

Abstract

In the last two decades radioimmunotherapy has been used as an additional treatment option for malignant glioma in several centers. More than 400 patients have been reported, who were treated in the framework of different studies. Most of them received labelled antibodies to tenascin, an extracellular matrix-glycoprotein, which is expressed in high amounts in malignant gliomas. We report side effects and survival time of 46 patients, treated after surgical resection and conventional radiotherapy with intralesionally injected labelled (131-Iodine) antibodies to tenascin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agboola O, Benoit B, Cross P, Da SV, Esche B, Lesiuk H, Gonsalves C (1998) Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys 42: 155–159

    PubMed  CAS  Google Scholar 

  2. Akabani G, Cokgor I, Coleman RE, Gonzalez TD, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, Zalutsky MR (2000) Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 8106 therapy. Int J Radiat Oncol Biol Phys 46: 947–958

    Article  PubMed  CAS  Google Scholar 

  3. Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pegram CN (1995) Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 8106 and anti-chondroitin proteoglycan sulfate Mel-14 F (ab’)2 — a preliminary report. J Neurooncol 24: 109–122

    Article  PubMed  CAS  Google Scholar 

  4. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR (1998) Iodine-131-labeled antitenascin monoclonal antibody 8106 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 16: 2202–2212

    PubMed  CAS  Google Scholar 

  5. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91: 2076–2080

    Article  PubMed  CAS  Google Scholar 

  6. Brady LW, Markoe AM, Woo DV, Rackover MA, Koprowski H, Steplewski Z, Peyster RG (1990) Iodine125 labeled anti-epidermal growth factor receptor-425 in the treatment of malignant astrocytomas. A pilotstudy. J Neurosurg Sci 34: 243–249

    CAS  Google Scholar 

  7. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P (1992) Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22: 225–230

    Article  PubMed  CAS  Google Scholar 

  8. Breyer R, Hussein S, Radu DL, Putz KM, Gunia S, Hecker H, Samii M, Walter GF, Stan AC (2000) Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J Neurosurg 92: 140–149

    Article  PubMed  CAS  Google Scholar 

  9. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE, Provenzale JM, Zalutsky MR, Bigner DD (2000) Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 8106 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18: 3862–3872

    PubMed  CAS  Google Scholar 

  10. Colapinto EV, Lee YS, Humphrey PA, Zalutsky MR, Friedman HS, Bullard DE, Bigner DD (1988) The localisation of radio-labelled murine monoclonal antibody 8106 and its Fab fragment in human glioma xenografts in athymic mice. Br J Neurosurg 2: 179–191

    Article  PubMed  CAS  Google Scholar 

  11. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704–710

    Article  PubMed  Google Scholar 

  12. Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg 88: 1973–1991

    Article  PubMed  CAS  Google Scholar 

  13. Emrich JG, Hand CM, Dilling TJ, Class R, Bender H, Brady LW (1997) Biodistribution of 125I-MAb 425 in a human glioma xenograft model: effect of chloroquine. Hybridoma 16: 93–100

    Article  PubMed  CAS  Google Scholar 

  14. Forsting M, Albert FK, Kunze S, Adams HP, Zenner D, Sartor K (1993) Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. AJNR Am J Neuroradiol 14: 77–87

    PubMed  CAS  Google Scholar 

  15. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH, Zaknoen SL (2002) A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neurooncol 4: 261–267

    CAS  Google Scholar 

  16. Goetz C, Riva P, Tatsch K, Gildehaus F-J, Reulen HJ (2003) Radioimmunotherapy in selected patients with malignant glioma, survival times and side effects. J Neurooncology 62: 321–328

    Article  CAS  Google Scholar 

  17. Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G (2002) Pretargeted adjuvant radioimmunotherapy with yttrium90-biotin in malignant glioma patients: a pilot study. Br J Cancer 86: 207–212

    Article  PubMed  CAS  Google Scholar 

  18. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH (2002) Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 98: 362–369

    Article  PubMed  CAS  Google Scholar 

  19. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT (1995) A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 34: 121131

    Article  Google Scholar 

  20. Jansen EP, Dewit LG, van Herk M, Bartelink H (2000) Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol 56: 151–156

    Article  PubMed  CAS  Google Scholar 

  21. Kulla A, Liigant A, Pnrsoo A, Rippin G, Asser T (2000) Tenascin expression patterns and cells of monocyte lineage: relationship in human gliomas. Mod Pathol 13: 56–67

    Article  PubMed  CAS  Google Scholar 

  22. Merlo A, Jermann E, Hausmann O, Chiquet-Ehrismann R, Probst A, Landolt H, Maecke HR, Mueller-Brand J, Gratzl O (1997) Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas. Int J Cancer 71: 810–816

    Article  PubMed  CAS  Google Scholar 

  23. Paganelli G, Bartolomei M, Ferrari M, Cremonesi M, Broggi G, Maira G, Sturiale C, Grana C, Prisco G, Gatti M, Caliceti P, Chinol M (2001) Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16: 227–235

    Article  PubMed  CAS  Google Scholar 

  24. Papanastassiou V, Pizer BL, Coakham HB, Bullimore J, Zananiri T, Kemshead JT (1993) Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br J Cancer 67: 144–151

    Article  PubMed  CAS  Google Scholar 

  25. Poepperl G, Goetz C, Gildehaus F-J, Yousry TA, Reulen HJ, Hahn K, Tatsch K (2002) Initial experience with locoregional radioimmunotherapy using 131I-labelled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV). Nuklearmedizin 41.120–128

    Google Scholar 

  26. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2002) Phase II trial of murine (131)í-labeled antitenascin monoclonal antibody 8106 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20: 1389–1397

    Article  PubMed  CAS  Google Scholar 

  27. Reulen HJ, Graham R, Spatz M, Klatzo I (1977) Role of pressure gradients and bulk flow in dynamics of vasogenic brain edema. J Neurosurg 46: 24–35

    Article  PubMed  CAS  Google Scholar 

  28. Riva P, Franceschi G, Arista A, Frattarelli M, Riva N, Cremonini AM, Giuliani G, Casi M (1997) Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 80: 2733–2742

    Article  PubMed  CAS  Google Scholar 

  29. Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini AM, Giuliani G, Casi M, Gentile R, Jekunen AA, Kairemo KJ (1999) 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma — phase I and II study. Acta Oncol 38: 351–359

    Article  PubMed  CAS  Google Scholar 

  30. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M (2000) Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 27: 601–609

    Article  PubMed  CAS  Google Scholar 

  31. Salminen E, Nuutinen JM, Huhtala S (1996) Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 32A: 1918–1923

    Article  Google Scholar 

  32. Schold SC Jr, Zalutsky MR, Coleman RE, Glantz MJ, Friedman AH, Jaszczak RJ, Bigner SH, Bigner DD (1993) Distribution and dosimetry of I-123-labeled monoclonal antibody 8106 in patients with anaplastic glioma. Invest Radiol 28: 488496

    Article  Google Scholar 

  33. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93: 1003–1013

    Article  PubMed  CAS  Google Scholar 

  34. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD (1992) Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 36: 41–55

    Article  PubMed  CAS  Google Scholar 

  35. Wurschmidt F, Bunemann H, Heilmann HP (1995) Prognostic factors in high-grade malignant glioma. A multivariate analysis of 76 cases with postoperative radiotherapy. Strahlenther Onkol 171: 315–321

    PubMed  CAS  Google Scholar 

  36. Zagzag D, Friedlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M, Cohen H, Grumet M, Greco MA (1995) Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 55: 907–914

    PubMed  CAS  Google Scholar 

  37. Zimmer AM, Kazikiewicz JM, Rosen ST, Spies SM (1987) Pharmacokinetics of 99mTc(Sn)- and 131I-labeled anti-carcinoembryonic antigen monoclonal antibody fragments in nude mice. Cancer Res 47: 1691–1694

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ludwig-Maximilians-Universität, Department of Neurosurgery, München, Germany

    C. Goetz, W. Rachinger, M. Decker, S. Stocker, J.-C. Tonn & H.-J. Reulen

  2. Ludwig-Maximilians-Universität, Department of Nuclear Medicine, München, Germany

    G. Poepper, F.-J. Gildehaus & K. Tatsch

  3. Department of Immunology, Eberhard-Karls-Universität, Institute for Cell Biology, Tübingen, Germany

    G. Jung

Authors
  1. C. Goetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Rachinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Poepper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Decker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F.-J. Gildehaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Stocker
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K. Tatsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J.-C. Tonn
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H.-J. Reulen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Neurochirurgie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

    M. Westphal

  2. Neurochirurgische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, München, Germany

    J.-C. Tonn

  3. Department of Neurosurgery, Tel Aviv Medical Center, Tel Aviv, Israel

    Z. Ram

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag/Wien

About this paper

Cite this paper

Goetz, C. et al. (2003). Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings. In: Westphal, M., Tonn, JC., Ram, Z. (eds) Local Therapies for Glioma Present Status and Future Developments. Acta Neurochirurgica Supplements, vol 88. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6090-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6090-9_12

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-40355-6

  • Online ISBN: 978-3-7091-6090-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation